Schizophrenia is a devastating mental illness characterized by symptoms eg hallucinations, disorganized thinking, loss of goal-directed behaviors and deterioration in social role functioning.
Positive or psychotic symptoms are delusions, hallucinations, and distorted perceptions.
Negative symptoms include flat or blunted emotions, lack of motivation or energy, lack of pleasure or interest in things, and limited speech.
Disorganized symptoms are confused thinking, disorganized speech and behavior.
Cognitive symptoms include impairment in attention verbal fluency memory, and executive functioning.
Several anti-inflammatory drugs, including aspirin, oestrogens, minocycline and N-acetylcysteine, appear to help mitigate symptom severity in patients with schizophrenia, according to a systematic review and meta-analysis.
Continuous primary care follow-up during the transition from adolescence to young adulthood could reduce the risk of mental illness-related hospitalizations post-transition in individuals with severe mental illness, according to a Canadian study.
Relapse in schizophrenia appears to contribute to increased treatment resistance, with a recent study showing that response to antipsychotic medication is reduced or delayed in patients who relapse after effective treatment of the first episode.
Children born to parents with schizophrenia are at increased risk of developing a variety of neurological disorders, as well as visual and hearing disorders, at an early age, a study has found. The same is true for those born to parents with a major depression.
Antipsychotic drug treatment appears to be less effective in patients with higher polygenic risk score (PRS) for schizophrenia, suggests a study. PRS burden appears to be useful as a prognostic biomarker.
Exposure to corticosteroids in patients with autoimmune hepatitis (AIH) appears to contribute to increased risks of cataract, diabetes and bone fractures, a study has found. Notably, the fracture risk is elevated at low doses, while the risk of adverse events overall is dose-dependent and is reversible.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Supplementation with oral nano vitamin D appears to moderate disease activity and severity grade of patients with active ulcerative colitis (UC), suggests a study, adding that this association is more evident in those achieving a target vitamin D level of 40 ng/mL.